Source: http://www.google.com/patents/USRE42524?dq=7125605
Timestamp: 2014-12-25 00:53:55
Document Index: 638173795

Matched Legal Cases: ['Application No. 02729092', 'Application No. 02729092', 'Application No. 2', 'Application No. 2', 'art 1', 'art 1', 'Application No. 2002259107', 'Application No. 2002259107', 'Application No. 2', 'Application No. 2', 'Application No. 05722719', 'Application No. 200580009719', 'Application No. 200580009719']

Patent USRE42524 - Colloidal metal compositions and methods - Google PatentsSearch Images Maps Play YouTube News Gmail Drive More »Sign inAdvanced Patent SearchPatentsThe present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene...http://www.google.com/patents/USRE42524?utm_source=gb-gplus-sharePatent USRE42524 - Colloidal metal compositions and methodsAdvanced Patent SearchPublication numberUSRE42524 E1Publication typeGrantApplication numberUS 11/923,344Publication dateJul 5, 2011Filing dateOct 24, 2007Priority dateApr 30, 2001Also published asUS7229841, US7387900, US8785202, US20020192814, US20030053983, US20070160572, US20070231408, US20100143298, US20120134956Publication number11923344, 923344, US RE42524 E1, US RE42524E1, US-E1-RE42524, USRE42524 E1, USRE42524E1InventorsLawrence Tamarkin, Giulio F. PaciottiOriginal AssigneeCytimmune Sciences, Inc.Export CitationBiBTeX, EndNote, RefManPatent Citations (103), Non-Patent Citations (138), Referenced by (1), Classifications (35), Legal Events (2) External Links: USPTO, USPTO Assignment, EspacenetColloidal metal compositions and methodsUS RE42524 E1Abstract The present invention comprises compositions and methods for delivery systems of agents, including therapeutic compounds, pharmaceutical agents, drugs, detection agents, nucleic acid sequences and biological factors. In general, these vector compositions comprise a colloidal metal, derivatized PEG (polyethylene glycol) and an agent. The invention also comprises methods and compositions for making such colloidal metal compositions and for treatment of cancer.
Patent CitationsCited PatentFiling datePublication dateApplicantTitleUS2768958Apr 8, 1954Oct 30, 1956Goodrich Co B FColloidal dispersions of heavy metal compoundsUS2785153Sep 13, 1954Mar 12, 1957Crookes Barnes Lab IncSilver proteinUS3145144Sep 28, 1960Aug 18, 1964Takeda Pharmacentical Ind LtdProcess for manufacturing chromium treated vaccinesUS3149036Oct 16, 1961Sep 15, 1964Merck & Co IncAdjuvant vaccine with aluminum monostearate, mannide monooleate, vegetable oil, and an aqueous phase immunolgical agentUS3269912Apr 8, 1963Aug 30, 1966Boehringer & Soehne GmbhAluminum oxide depot vaccinesUS3399263Apr 12, 1965Aug 27, 1968American Cyanamid CoStable adjuvant emulsion compositions comprising the hydrated reaction products of a methallic cation and a fatty acidUS3531565Sep 25, 1969Sep 29, 1970American Cyanamid CoStable adjuvant emulsion compositions comprising hydrated salts of a polyvalent metallic cation and a higher fatty acidUS3577523Mar 7, 1969May 4, 1971Miles LabWater-insoluble antigenic substances and method of preparing the same and antigenic depot agents incorporating such substancesUS3651211Oct 16, 1967Mar 21, 1972Lockheed Aircraft CorpVirus inactivationUS3819820Sep 18, 1969Jun 25, 1974Aluisy RIrradiated substance and compound and method of preparing the sameUS3919413Nov 29, 1974Nov 11, 1975Univ NebraskaVaccine for neonatal calf diarrheaUS3983228Nov 19, 1974Sep 28, 1976Merck & Co., Inc.Water-in-oil adjuvant compositionUS4016252Dec 11, 1975Apr 5, 1977Institut PasteurCalcium phosphate gel for adsorbing vaccinesUS4053587Jan 10, 1975Oct 11, 1977Research CorporationMethod of treating viral infectionsUS4069313Apr 7, 1976Jan 17, 1978Merck & Co., Inc.Aluminum monostearate stabilizerUS4177263Dec 27, 1976Dec 4, 1979Research CorporationChloroplatinumammineUS4196185Jun 5, 1978Apr 1, 1980Hoffmann-La Roche Inc.Radiolabeled n-(4-hydroxy-2-phenylethyl)-4-(1-(piperidinyl)cyclohexyl)benzamideUS4197237Feb 12, 1975Apr 8, 1980Syva CompanyFor use in radioimmunoassayUS4197286Sep 27, 1977Apr 8, 1980Southwest Research InstituteTestosterone derivatives and assay methodUS4213964Dec 7, 1978Jul 22, 1980Miles Laboratories, Inc.ImmunoassayUS4215036Aug 15, 1978Jul 29, 1980Research CorporationModified grass pollen antigensUS4218436Apr 26, 1979Aug 19, 1980The Upjohn CompanyCompounds and methodsUS4329281Dec 21, 1979May 11, 1982Hoffmann-La Roche Inc.Hapten compositionsUS4330530Dec 22, 1980May 18, 1982The Procter & Gamble CompanyAnti-arthritic compositions and method using gold salts and organophosphonatesUS4332787Jun 23, 1980Jun 1, 1982The Massachusetts General HospitalAssay for beta-adrenergic antagonists and antibody thereforUS4339437Jul 26, 1979Jul 13, 1982Research CorporationAnti-tumor methodUS4346074Aug 16, 1979Aug 24, 1982National Research Development Corp.Pasteurellosis vaccinesUS4451570Mar 26, 1981May 29, 1984The Regents Of The University Of CaliforniaImmunoglobulin-secreting human hybridomas from a cultured human lymphoblastoid cell lineUS4487780Feb 5, 1982Dec 11, 1984Scheinberg Israel HSubstituted cysteine compoundsUS4578270Feb 22, 1984Mar 25, 1986Human Oltoanyagtermelo Es Kutato IntezetProcess for the preparation of lyophilized, adsorbed polyvalent vaccinesUS4594325Mar 26, 1981Jun 10, 1986The Regents Of The University Of Calif.High fusion frequency fusible lymphoblastoid cell lineUS4608252Sep 27, 1985Aug 26, 1986Syntex (U.S.A.) Inc.Chloramphenicol derivatives antigens and antibodiesUS4624921Apr 26, 1984Nov 25, 1986Cetus CorporationCultures, fusionUS4624923Jan 24, 1986Nov 25, 1986Yeda Research And Development Company LimitedMetal-coated polyaldehyde microspheresUS4639336Jun 14, 1984Jan 27, 1987Roussel UclafNovel radioactive estradienes labelled with iodineUS4657763Sep 3, 1985Apr 14, 1987Michael EbertCombined chrysotherapeutic agents for autoimmune diseasesUS4693975Nov 20, 1984Sep 15, 1987The Wistar InstituteFusion of lymphoblastoid and plasma cytoma cellsUS4710378Mar 8, 1985Dec 1, 1987Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteGenetically engineered antigen adsorbed on aluminum gel with stabilizerUS4720459Feb 14, 1985Jan 19, 1988Medical College Of Wisconsin Research Foundation, Inc.Myelomas for producing human/human hybridomasUS4740589Jul 11, 1986Apr 26, 1988Burroughs Wellcome Co.Capsular polysaccharide metal complex vaccinesUS4744760Jan 14, 1985May 17, 1988University Of British ColumbiaStability; cationic polysaccharide derivativeUS4753873Feb 3, 1986Jun 28, 1988Cambridge Bioscience CorporationPeptides for the diagnosis of HTLV-III antibodies, their preparation and useUS4812556May 18, 1987Mar 14, 1989VirovahlImmunoassay for aidsUS4880750Jul 9, 1987Nov 14, 1989Miragen, Inc.Antigens, analyzing, immunologyUS4882423Mar 30, 1987Nov 21, 1989Calpis Food IndustrySubstance-conjugated complement component C1qUS4906564Mar 13, 1987Mar 6, 1990The United States Of America As Represented By The Secretary Of The ArmyAntigenic determinants recognized by antibodies obtained using a pathogenic agent or a derivative thereof that presents a restricted set of antigensUS4977286Sep 9, 1988Dec 11, 1990Trustees Of The University Of PennsylvaniaGlycolipidsUS5017687Jun 13, 1988May 21, 1991Virovahl, S.A.Polypeptides Immunologically Reactive With HTLV AntibodiesUS5019497Jul 5, 1988May 28, 1991Lennart OlssonHuman squamous lung carcinoma cell specific antigens and antibodiesUS5035995May 22, 1989Jul 30, 1991Calpis Food Industry Co., Ltd.Test method involving substance-conjugated complement component C1qUS5089424Oct 23, 1989Feb 18, 1992Abbott LaboratoriesMethod and apparatus for heterogeneous chemiluminescence assayUS5112606Sep 29, 1989May 12, 1992Sadao ShiosakaMethod of producing antibodies using colloidal metal as carrierUS5126253Sep 25, 1986Jun 30, 1992Suntory LimitedProduction of monoclonal antibodiesUS5169754Oct 31, 1990Dec 8, 1992Coulter CorporationBiodegradable particle coatings having a protein covalently immobilized by means of a crosslinking agent and processes for making sameUS5213804Jan 15, 1991May 25, 1993Liposome Technology, Inc.Localized delivery of antibiotic to tumor via bloodstream, encapsulation in liposomeUS5242828Nov 9, 1989Sep 7, 1993Pharmacia Biosensor AbSensing surfaces capable of selective biomolecular interactions, to be used in biosensor systemsUS5248772Jan 29, 1992Sep 28, 1993Coulter CorporationFormation of colloidal metal dispersions using aminodextrans as reductants and protective agentsUS5264221May 22, 1992Nov 23, 1993Mitsubishi Kasei CorporationLiposomes with maleimide groups bonded to thiol groups in proteins for antitumor agentsUS5294369Dec 5, 1990Mar 15, 1994Akzo N.V.Alkanethiol, dithiol, and trithiol coatings; diagnostic kits for immunoassayUS5376556Sep 11, 1992Dec 27, 1994Abbott LaboratoriesSurface-enhanced Raman spectroscopy immunoassayUS5384073Jan 21, 1994Jan 24, 1995Akzo N.V.Ligand gold bondingUS5434088May 24, 1994Jul 18, 1995Tosoh CorporationMethod of and kit for energy transfer immunoassay with colloidal particlesUS5436161Jul 22, 1994Jul 25, 1995Pharmacia Biosensor AbMatrix coating for sensing surfaces capable of selective biomolecular interactions, to be used in biosensor systemsUS5446090Nov 12, 1993Aug 29, 1995Shearwater Polymers, Inc.Isolatable, water soluble, and hydrolytically stable active sulfones of poly(ethylene glycol) and related polymers for modification of surfaces and moleculesUS5466609Oct 29, 1992Nov 14, 1995Coulter CorporationImmunoassayUS5498421Feb 22, 1994Mar 12, 1996Vivorx Pharmaceuticals, Inc.Composition useful for in vivo delivery of biologics and methods employing sameUS5521289Jul 29, 1994May 28, 1996Nanoprobes, Inc.Small organometallic probesUS5639725Apr 26, 1994Jun 17, 1997Children's Hospital Medical Center Corp.Angiostatin proteinUS5686578Aug 5, 1994Nov 11, 1997Immunomedics, Inc.Polyspecific immunoconjugates and antibody composites for targeting the multidrug resistant phenotypeUS5736410Jun 7, 1995Apr 7, 1998Sri InternationalLight emitter(with activator) and detector for wavelengths emitted by analytes bound to phosphors which absorb low frequency radiation and emit higher frequency radiation, for immunoassays and other diagnostic measurementsUS5874226May 22, 1995Feb 23, 1999H. Lee BrowneIn situ immunodetection of antigensUS5921927Nov 12, 1997Jul 13, 1999Axialtome Australia Pty. Ltd.Positioning method and apparatus for X-ray tomographyUS5972720Jun 5, 1997Oct 26, 1999Roche Diagnostics GmbhColloidal particles surface are co-adsorbed with biomolecules and polyoxyethylene qlycol substituted by thiol and/or disulfide groups; as detection reagent in an immunoassayUS6235093Jun 28, 1999May 22, 2001Daiwa Fine Chemicals Co., Ltd.Solutions of water and noble metals for reductionUS6274552 *Nov 10, 1997Aug 14, 2001Cytimmune Sciences, Inc.Targeting tissue with tumor necrosis factor mixed or bound to colloidal metal; anticarcinogenic agents, autoimmune diseasesUS6407218Nov 10, 1998Jun 18, 2002Cytimmune Sciences, Inc.Monoclonal antibodies, antigen specific for immunologyUS6447765Mar 3, 1999Sep 10, 2002University Of Southern CaliforniaUse of cytokines and mitogens to inhibit graft versus host diseaseUS6528051Aug 22, 2001Mar 4, 2003Cytimmune Sciences, Inc.Methods and compositions for enhancing immune responseUS6528485 *Jun 5, 2000Mar 4, 2003Applied Research Systems Ars Holding N.V.Human growth hormone releasing factor-PEG conjugates; PEG unit is covalently bound to the amino group of Lys21 of SEQ ID NO:1; the hGRF-PEG conjugate does not contain a triazine groupUS6530944Feb 8, 2001Mar 11, 2003Rice UniversityLocalized delivery of heat and biological imaging materialsUS6541617Oct 27, 1999Apr 1, 2003Clinical Micro Sensors, Inc.Colloid hybrid labeled detector; nucleic acidsUS6624886May 13, 2002Sep 23, 2003Surromed, Inc.SERS substrates formed by hydroxylamine seeding of colloidal metal nanoparticle monolayersUS6660058Aug 22, 2000Dec 9, 2003Nanopros, Inc.Preparation of silver and silver alloyed nanoparticles in surfactant solutionsUS6869932Nov 20, 2002Mar 22, 2005Applied Research Systems Ars Holding N.V.Immobilizated growth hormone releasing factorUS7229841Mar 8, 2002Jun 12, 2007Cytimmune Sciences, Inc.Expression vector for use treatment of cancerUS20010055581Mar 9, 2001Dec 27, 2001Lawrence TamarkinAdmixture of a colloidal metal and a biologically-active factor; colloidal metal reduces or eliminated toxicity so the factor can have therapeutic effect; vaccines, treating cancerUS20020103517Feb 8, 2001Aug 1, 2002West Jennifer L.Optically-active nanoparticles for use in therapeutic and diagnostic methodsUS20020192814Mar 8, 2002Dec 19, 2002Lawrence TamarkinColloidal metal compositions and methodsUS20030053983Apr 30, 2002Mar 20, 2003Lawrence TamarkinColloidal metal compositions and methodsUS20030180252Dec 19, 2002Sep 25, 2003Lawrence TamarkinMethods and compositions for enhancing immune response and for the production of in vitro MabsUS20040018203 *Jun 8, 2001Jan 29, 2004Ira PastanConnector molecule attaching a targeting molecule to an effector molecule is conjugated to polyethylene glycol (peg) moleculesUS20040029794Nov 20, 2002Feb 12, 2004Applied Research Systems Ars Holding N.V.Immobilizated growth hormone releasing factorUS20040180002Mar 26, 2004Sep 16, 2004Young David S. F.production of anti-cancer antibodies for therapeutic and diagnostic purposes. The antibodies can be used in aid of staging and diagnosis of a cancer, and can be used to treat primary tumors and tumor metastases. The anti-cancer antibodies can be conjugated to toxins, enzymes, radioactive compounds,US20040213760Sep 26, 2003Oct 28, 2004Lawrence TamarkinComposition and method for delivery of biologically-active factorsUS20050003431Jul 21, 2004Jan 6, 2005Wucherpfennig Kai W.Monovalent, multivalent, and multimeric MHC binding domain fusion proteins and conjugates, and uses thereforAU757857B2 Title not availableAU760035B2 Title not availableAU2003204353B2 Title not availableCA2158475A1Mar 18, 1994Sep 29, 1994Cytimmune Sciences IncComposition and method for reducing toxicity of biologically-active factorsEP0044722A1Jul 16, 1981Jan 27, 1982The Board Of Trustees Of The Leland Stanford Junior UniversityHuman hybridomas, precursors and productsEP0156242A2Mar 12, 1985Oct 2, 1985Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteLyophilized hepatitis B vaccineEP0179483A2Oct 25, 1985Apr 30, 1986Juridical Foundation The Chemo-Sero-Therapeutic Research InstituteMethod for preparing monoclonal antibodies to HBsAgWO1999024077A2 *Nov 10, 1998May 20, 1999Cytimmune Sciences IncCompositions and methods for targeted delivery of biologically-active factors* Cited by examinerNon-Patent CitationsReference1Author: Balkwill et al., Title: The Cytokine Network, Publ: Immunology Today, vol./Iss: 10(9), pp. 299-304, Date: Jan. 1, 1989.2Author: Brust et al., Title: Novel Gold-Dithiol Nano-Networks with Non-Metalhe Electronic Properties, Publ: Advanced Materials, vol./Iss: 7(9), pp. 795-797, Date: Jan. 1, 1995.3Author: Calabrese et al., Title: Chemotherapy of Neoplastic Diseases, Publ: Goodman & Gilman's The Pharmacological Basis of Therapeutics, vol./Iss: 9th Edition, pp. 1260-1261, Date: Jan. 1, 1996.4Author: Carter et al., Title: Appendix C, Publ: Chemotherapy of Cancer, vol./Iss: 2nd Ed., pp. 361-367, Date: Jan. 1, 1981.5Author: Ciesiolka et al., Title: An 8- to 10-fold Enhancement in Sensitivity for Quanitation of Proteins by Modified Application of Colloidal Gold (Abstract Only-Applicants do not have complete copy), Publ: Analytical Biochemistry, vol./Iss: 168 (2), pp. 280-283, Date: Feb. 1, 1988.6Author: Ciesiolka et al., Title: An 8- to 10-fold Enhancement in Sensitivity for Quanitation of Proteins by Modified Application of Colloidal Gold (Abstract Only�Applicants do not have complete copy), Publ: Analytical Biochemistry, vol./Iss: 168 (2), pp. 280-283, Date: Feb. 1, 1988.7Author: Cohen, I., Title: Optimization of Dose-Time Factors for a Tumor and Multiple Associated Normal Tissues, Publ: International Journal of Radiation Oncology, vol./Iss: 13, pp. 251-258, Date: Jan. 1, 1987.8Author: Coulombe et al., Title: Cytochemical Demonstrations of Increased Phospholipid Content in Cell Membranes in Chlorphentermine-Induced Phospholipidosis, Publ: Journal of Histochemistry and Cytochemistry, vol./Iss: 37(2), pp. 139-147, Date: Jan. 1, 1989.9Author: De Roe et al., Title: A Model of Protein-Colloidal Gold Interactions, Publ: The Journal of Histochemistry and Cytochemistry, vol./Iss: 35(11), pp. 1191-1198, Date: Jan. 1, 1987.10Author: De Roe et al., Title: A Model of Protein�Colloidal Gold Interactions, Publ: The Journal of Histochemistry and Cytochemistry, vol./Iss: 35(11), pp. 1191-1198, Date: Jan. 1, 1987.11Author: Debrabander et al., Title: Probing Microtobule-Dependent Intracellular Motility with Nanometre Particle Video Ultramicroscopy (nanovid ultramicroscopy) (Abstract Only-Applicants do not have complete copy), Publ: Cytobio, vol./Iss: 43, pp. 273-283, Date: Jan. 1, 1985.12Author: Debrabander et al., Title: Probing Microtobule-Dependent Intracellular Motility with Nanometre Particle Video Ultramicroscopy (nanovid ultramicroscopy) (Abstract Only�Applicants do not have complete copy), Publ: Cytobio, vol./Iss: 43, pp. 273-283, Date: Jan. 1, 1985.13Author: Deng et al., Title: Self-Assembled Monolayers of Alkanethiolates Presenting Tri(propylene sulfoxide) Groups Resist the Adsorption of Protein, Publ: Journal of the American Chemical Society, vol./Iss: 118(19), pp. 5136-5137, Date: May 15, 1996.14Author: Dominguez et al., Title: Effect of Heat Treatment on the Antigen-Binding of Anti-Peroxidase Immunoglobulins in Bovine Colstrum, Publ: Journal of Dairy Science, vol./Iss: 80(12), pp. 3182-3187, Date: Dec. 1, 1998.15Author: Eck et al., Title: Chapter 5: Gene-Based Therapy, Publ: Goodman & Gilman's The Pharmacological Basis of Therapeutics, vol./Iss:, pp. 77-101, Date: Jan. 1, 1996.16Author: Elliott et al., Title: Analysis of Colloidal Gold Probes by Isoelectric Focusing in Agarose Gels (Abstract Only-Applicants do not have complete copy), Publ: Analytical Biochemisty, vol./Iss: 186(1), pp. 53-59, Date: Apr. 1, 1990.17Author: Elliott et al., Title: Analysis of Colloidal Gold Probes by Isoelectric Focusing in Agarose Gels (Abstract Only�Applicants do not have complete copy), Publ: Analytical Biochemisty, vol./Iss: 186(1), pp. 53-59, Date: Apr. 1, 1990.18Author: EPO Searching Authority, Title: Search Report EPO-Application No. 02729092.3, Publ: EPO Search Report, vol./Iss:, pp. 1-6, Date: Jul. 13, 2009.19Author: EPO Searching Authority, Title: Search Report EPO�Application No. 02729092.3, Publ: EPO Search Report, vol./Iss:, pp. 1-6, Date: Jul. 13, 2009.20Author: Fraker et al., Title: Passive Immunization Against Tumor Necrosis Factor Partially Abrogates Interleukin 2 Toxicity, Publ: The Journal of Experimental Medicine, vol./Iss: 170, pp. 1015-1020, Date: Jan. 1, 1989.21Author: Fujimoto, D.-CA Office Action, Title: Canadian Office Action cited in CA Application No. 2,448,607, Publ: Canadian Office Action, vol./Iss:, pp. 1-2, Date: Oct. 12, 2010.22Author: Fujimoto, D.�CA Office Action, Title: Canadian Office Action cited in CA Application No. 2,448,607, Publ: Canadian Office Action, vol./Iss:, pp. 1-2, Date: Oct. 12, 2010.23Author: Goldstein et al., Title: Cardiovascular Effects of Platelet-Activating Factor, Publ: Lipids, vol./Iss: 26(212), pp. 1250-1256, Date: Jan. 1, 1991.24Author: Grainger et al., Title: Polymeric Monolayers on Solid Substrates by Spontaneous Adsorption from Solution, Publ: American Chemical Society-Abstracts of Papers, vol./Iss: Part 1, Pages: Paragraph 074, Date: Aug. 20, 1995.25Author: Grainger et al., Title: Polymeric Monolayers on Solid Substrates by Spontaneous Adsorption from Solution, Publ: American Chemical Society�Abstracts of Papers, vol./Iss: Part 1, Pages: Paragraph 074, Date: Aug. 20, 1995.26Author: Gref et al., Title: The Controlled Intravenous Delivery of Drugs using PEG-Coated Sterically Stabilized Nanospheres, Publ: Advanced Drug Delivery Reviews, vol./Iss: 16, pp. 215-233, Date: Jan. 1, 1995.27Author: Gura, T., Title: Systems for Identifying New Drug are Often Faulty, Publ: Science, vol./Iss: 278, pp. 1041-1042, Date: Nov. 7, 1997.28Author: Hashimoto et al., Title: Action Site of Circulating Interleukin-1 on the Rabbit Brain, Publ: Brain Research, vol./Iss: 540, pp. 217-223, Date: Jan. 1, 1991.29Author: Hisamatsu et al., Title: Platelet Activating Factor Induced Respiratory Mucosal Damage, Publ: Lipds, vol./Iss: 26(12), pp. 1287-1291, Date: Jan. 1, 1991.30Author: Hopkins et al., Title: Early Events Following the Binding of Epidermal Growth Factor to Surface Receptors on Ovarian Granulosa Cells, Publ: European Journal of Cell Biology, vol./Iss: 24, pp. 259-264, Date: Jan. 1, 1981.31Author: IBM TDB et al., Title: Molecular Glue for Highly Controlled Attachment of Macromolecules to Metals, Publ: IBM Technical Bulletin, vol./Iss: 39(09), pp. 1-5, Date: Sep. 1, 1996.32Author: Illum et al., Title: Development of Systems for Targeting the Regional Lymph Nodes for Diagnostic Imaging: In Vivo Behavior of Colloidal PEG-Coated Magnetic Nanospheres in the Rat Following Intestinal Administration, Publ: Pharmaceutical Research, vol./Iss: 18(5), pp. 640-645, Date: Jan. 1, 2001.33Author: Japanese Patent Office, Title: Japanese Patent Application 2000-520153 Office Action as translated by Foreign Associate, Publ: Japanese Office Action, vol./Iss:, pp. 1-10, Date: Oct. 6, 2009.34Author: Japanese Publication, Title: Japanese Laid-Open Publication No. 9-107980 English Abstract only-of Japanese Patent Application 08-231415, Publ:, vol./Iss:, pp. 1-3, Date: Apr. 28, 1997.35Author: Japanese Publication, Title: Japanese Laid-Open Publication No. 9-107980 English Abstract only�of Japanese Patent Application 08-231415, Publ:, vol./Iss:, pp. 1-3, Date: Apr. 28, 1997.36Author: Kang et al., Title: Ultrastructural and Immunocytochemical Study of the Uptake and Distribution of Bacterial Lipopolysaccharide in Human Monocytes, Publ: Journal of Leukemia Biology, vol./Iss: 48, pp. 316-332, Date: Jan. 1, 1990.37Author: Kirchner et al., Title: The Development of Neutralizing Antibodies in a Patient Receiving Subcutaneous Recombinant and Natural Interleukin-2, Publ: Cancer, vol./Iss: 67(7), pp. 1862-1864, Date: Apr. 1, 1991.38Author: Klotz et a., Title: Macromolecule-Small Molecule Interactions: Strong Binding by Intramolecularly Cross-Linked Polylysine, Publ: Biochemistry, vol./Iss: 10(6), pp. 923-926, Date: Jan. 1, 1971.39Author: Koning, et al., Title: Selective Transfer of a Lipophilic Prodrug of 5-Fluorodeoxyuridine from Immunoliposomes to Colon Cancer Cells, Publ: Biochimica et Biphysica Acta, vol./Iss: 1420, pp. 153-167, Date: Jun. 2, 1999.40Author: Krontiris, T.G., Title: Chapter 71: Molecular and Cellular Biology of Cancer, Publ: Internal Medicine, vol./Iss: 4th Ed., pp. 699-729, Date: Jan. 1, 1994.41Author: Lang et al., Title: A New Class of Thiolipids for the Attachment of Lipid Bilayers on Gold Surfaces, Publ: Langmuit, vol./Iss: 10(1), pp. 197-210, Date: Jan. 1, 1994.42Author: Lanzavecchia, Title: Identifying Strategies for Immune Interveator, Publ: Science, vol./Iss: 260, pp. 937-944, Date: Jan. 1, 1993.43Author: Lemmon et al., Title: Preparation and Characterization of Nanocomposites of Poly(ethylene oxide) with Layered Solids, Publ:, vol./Iss:, pp. 43-54, Date: Jan. 1, 1995.44Author: Leuvering et al., Title: A Sol Particle Agglutination Assay for Human Chorionic Gonadotrophin (Abstract Only-Applicants do not have complete copy), Publ: Journal of Immunological Methods, vol./Iss: 45(2), pp. 183-194, Date: Jan. 1, 1981.45Author: Leuvering et al., Title: A Sol Particle Agglutination Assay for Human Chorionic Gonadotrophin (Abstract Only�Applicants do not have complete copy), Publ: Journal of Immunological Methods, vol./Iss: 45(2), pp. 183-194, Date: Jan. 1, 1981.46Author: Lezzi et al., Title: Chelating Resins Supporting Dithiocarbamate and Methylthiourea Groups in Adsorption of Heavy Metal Ions, Publ: Journal of Applied Polymer Science, vol./Iss: 54(7), pp. 889-897, Date: Nov. 14, 1994.47Author: Lezzi et al., Title: Synthesis of Thiol Chelating Resins and Their Adsorption Properties toward Heavy Metal Ions, Publ: Journal of Polymer Science, vol./Iss: 32, pp. 1877-1883, Date: Jan. 1, 1994.48Author: Li et al., Title: Plasma Protein Interactions with Copolymer-Stabilized Colloids, Publ: Dissertation Abstracts International, vol./Iss: 54(7), pp. 3735-B, Date: Jan. 1, 1994.49Author: Magez et al., Title: Specific Uptake Tumor Necrosis Factor-a is Involved in Growth Control of Trypanosoma brucei, Publ: The Journal of Cell Biology, vol./Iss: 137(3), pp. 715-727, Date: May 5, 1997.50Author: Magez et al., Title: Specific Uptake Tumor Necrosis Factor�a is Involved in Growth Control of Trypanosoma brucei, Publ: The Journal of Cell Biology, vol./Iss: 137(3), pp. 715-727, Date: May 5, 1997.51Author: Marshall, E., Title: Gene Therapy's Growing Pains, Publ: Science, vol./Iss: 269(5227), pp. 1050-1055, Date: Aug. 25, 1995.52Author: Maruyama et al., Title: Targeting Efficiency of PEG-Immunoliposome-Conjugated Antibodies at PEG Terminals (Abstract Only-Applicants do not have comple copy), Publ: Advanced Drug Delivery Reviews, vol./Iss: 24, pp. 235-242, Date: Mar. 17, 1997.53Author: Mathias et al., Title: Sulfur-Substituted Polyoxyethylenes Sequential Ether-Thioether Copolymers, Publ: Crown Ethers and Phase Transfer Catalysis in Polymer Science, vol./Iss:, pp. 359-370, Date: Jan. 1, 1984.54Author: Morris et al., Title: Validation of the Biotinyl Ligant-Avidin-Gold Technique, Publ: Cyctochemistry, vol./Iss: 40, pp. 711-721, Date: Jan. 1, 1992.55Author: Mrksich et al., Title: Surface Plasmon Resonance Permits in Situ Measurement of Protein Adsorption on Self-Assembled Monolayers of Alkanethiolates on Gold, Publ: Langmuir, vol./Iss: 11, pp. 4383-4385, Date: Jan. 1, 1995.56Author: Nakashima et al., Title: Electrochemical Characterization of an Assembled Monolayers of alpha-Methoxy-omegamercapto-poly(ethylene glycol) on Gold and Complex Formation of the Monolayer with alpha-Cyclodextrin, Publ: Chemistry Letters, vol./Iss:, pp. 731-732, Date: Jan. 1, 1996.57Author: Nakashima et al., Title: Electrochemical Characterization of an Assembled Monolayers of α-Methoxy-ωmercapto-poly(ethylene glycol) on Gold and Complex Formation of the Monolayer with α-Cyclodextrin, Publ: Chemistry Letters, vol./Iss:, pp. 731-732, Date: Jan. 1, 1996.58Author: Niwa et al., Title: Two-Dimensional Array of Poly(methacrylic acid) Brushes on Gold Substrates. Interaction with Ferrocen-Terminated Poly(oxyethylene)s, Publ: Macromolecules, vol./Iss: 28(23), pp. 7770-7774, Date: Nov. 6, 1995.59Author: Ormann et al., Title: Expression of Tumor Necrosis Factor-alpha Receptors on Bovine Macrophages, Lymphocytes and Polymorphonuclear Luekocytes Internalization of Receptor-Bound Ligand, and Some Functional Effects, Publ: Lymphokine Research, vol./Iss: 9(1), pp. 43-58, Date: Jan. 1, 1990.60Author: Ormann et al., Title: Expression of Tumor Necrosis Factor-α Receptors on Bovine Macrophages, Lymphocytes and Polymorphonuclear Luekocytes Internalization of Receptor-Bound Ligand, and Some Functional Effects, Publ: Lymphokine Research, vol./Iss: 9(1), pp. 43-58, Date: Jan. 1, 1990.61Author: Otsuka et el., Title: Quantitative and Reversible Lectin-Induced Association of Gold Nanoparticles Modified with alpha-Lactosyl-omega-mercapto-poly(ethylene glycol), Publ: Journal of the American Chemical Society, vol./Iss: 123, pp. 8226-8230, Date: Feb. 20, 2001..62Author: Otsuka et el., Title: Quantitative and Reversible Lectin-Induced Association of Gold Nanoparticles Modified with α-Lactosyl-ω-mercapto-poly(ethylene glycol), Publ: Journal of the American Chemical Society, vol./Iss: 123, pp. 8226-8230, Date: Feb. 20, 2001..63Author: Paciotti et al., Title: (XP-001537146) #3858-Comparison of the Toxicity and Pharmacokinetics of Neat and Colloidal Gold Bound TNF, Publ: Proceedings of the American Association for Cancer Research, vol./Iss: 40, pp. 585, Date: Mar. 1, 1999.64Author: Paciotti et al., Title: (XP-001537146) #3858�Comparison of the Toxicity and Pharmacokinetics of Neat and Colloidal Gold Bound TNF, Publ: Proceedings of the American Association for Cancer Research, vol./Iss: 40, pp. 585, Date: Mar. 1, 1999.65Author: Paciotti et al., Title: (XP-001537149) #1048-The Use of Colloidal Gold in Cytokine Immunotherapy, Publ: Proceedings of the American Association for Cancer Research, vol./Iss: 39, pp. 153, Date: Mar. 1, 1998.66Author: Paciotti et al., Title: (XP-001537149) #1048�The Use of Colloidal Gold in Cytokine Immunotherapy, Publ: Proceedings of the American Association for Cancer Research, vol./Iss: 39, pp. 153, Date: Mar. 1, 1998.67Author: Paciotti et al., Title: Interleukin 1 Directly Regulates Hormone-Dependent Human Breast Cancer Cell Proliferation in Vivo, Publ: Molecular Endocrinology, vol./Iss: 2, pp. 459-464, Date: Jan. 1, 1988.68Author: Paciotti et al., Title: Interleukin 1alpha Differentially Synchronizes Estrogen Dependent and Estrogen-Independent Human Breast Cells in G0/G1 Phase of the Cell Cycle, Publ: Anti-Cancer Research, vol./Iss: 11, pp. 25-32, Date: Jan. 1, 1991.69Author: Paciotti et al., Title: Interleukin 1α Differentially Synchronizes Estrogen Dependent and Estrogen-Independent Human Breast Cells in G0/G1 Phase of the Cell Cycle, Publ: Anti-Cancer Research, vol./Iss: 11, pp. 25-32, Date: Jan. 1, 1991.70Author: Paciotti et al., Title: Interleukin 2 Differentially Effects the Proliferation of a Hormone-Dependent and a Hormone-Independent Human Breast Cancer Cell Line in Vitro and in Vivo, Publ: Anti-Cancer Research, vol./Iss: 8, pp. 1233-1249, Date: Jan. 1, 1988.71Author: Peters et al., Title: Binding and Internalization of Biotinylated Interleukin-2 in Human Lymphocytes, Publ: Blood, vol./Iss: 76, pp. 97-104, Date: Jan. 1, 1990.72Author: Prakken et al., Title: Artificial Antigen-Presenting Cells as a Tool to Exploit the Immune �Synapse�, Publ: Nature Medicine, vol./Iss: 6(12), pp. 1406-1410, Date: Dec. 1, 2000.73Author: Prakken et al., Title: Artificial Antigen-Presenting Cells as a Tool to Exploit the Immune 'Synapse', Publ: Nature Medicine, vol./Iss: 6(12), pp. 1406-1410, Date: Dec. 1, 2000.74Author: Prime et al., Title: Adsorption of Proteins onto Surfaces Containing End-Attached Oligo(ethylene oxide): A Model System Using Self-Assembled Monolayers, Publ: Journal of the American Chemical Society, vol./Iss: 115, pp. 10714-10721, Date: Jan. 1, 1993.75Author: Rabolt, J.F., Title: Design and Construction of Two Component Heterogenous Polymer Surfaces by Self Assembly, Publ: Polymer Preprints, vol./Iss: 36(1), pp. 84, Date: Apr. 1, 1995.76Author: Roitt et al., Title: The Cytokine Network, Publ: Immunology, vol./Iss: 3rd Ed., pp. 8-15, Date: Jan. 1, 1993.77Author: Ross et al., Title: Gene Therapy in the United States: A Five-Year Status Report, Publ: Human Gene Therapy, vol./Iss: 7, pp. 1781-1790, Date: Sep. 10, 1996.78Author: Rubanyi, G.M., Title: The Future of Human Gene Therapy, Publ: Molecular Aspects of Medicine, vol./Iss: 22, pp. 113-142, Date: Jan. 1, 2001.79Author: Schmitmeier et al., Title: Anti-Invasive Effect of Contortrostatin. A snake Venom Disintegrin, and TNF-alpha on Malignant Glioma Cells-(Applicants do not have complete copy), Publ: Anti-Cancer Research, vol./Iss: 20(6B), pp. 4227-4233, Date: Nov. 1, 2000.80Author: Tannock et al., Title:, Publ: The Basic Science of Oncology, vol./Iss: 2nd Ed., pp. 352-353, Date: Jan. 1, 1992.81Author: Tomii et al., Title: Production of Anti-Platelet-Activating Factor Antibodies by the Use of Colloidal Gold as Cancer, Publ: Japane Journal of Medicinal Science and Biology, vol./Iss: 44, pp. 75-80, Date: Jan. 1, 1991.82Author: USPTO, Title: USPTO Office Action-cited 11/516,175, Publ: USPTO Office Action, vol./Iss:, pp. 1-9, Date: Jun. 5, 2009.83Author: USPTO, Title: USPTO Office Action�cited 11/516,175, Publ: USPTO Office Action, vol./Iss:, pp. 1-9, Date: Jun. 5, 2009.84Author: USPTO, Title: USPTO Office Action-cited in 11/516,175, Publ: USPTO Office Action, vol./Iss:, pp. 1-10, Date: Sep. 11, 2009.85Author: USPTO, Title: USPTO Office Action�cited in 11/516,175, Publ: USPTO Office Action, vol./Iss:, pp. 1-10, Date: Sep. 11, 2009.86Author: USPTO, Title: USPTO Office Action-cited in 11/805,383, Publ: USPTO Office Action, vol./Iss:, pp. 1-16, Date: Apr. 17, 2009.87Author: USPTO, Title: USPTO Office Action�cited in 11/805,383, Publ: USPTO Office Action, vol./Iss:, pp. 1-16, Date: Apr. 17, 2009.88Author: USPTO, Title: USPTO Office Action-cited in 11/805,383, Publ: USPTO Office Action, vol./Iss:, pp. 1-33, Date: Aug. 19, 2009.89Author: USPTO, Title: USPTO Office Action�cited in 11/805,383, Publ: USPTO Office Action, vol./Iss:, pp. 1-33, Date: Aug. 19, 2009.90Author: Van Den Pol, A. N., Title: Colloidal Gold and Biotin-Avidin Conjugates as Ultrasound Markers for Neural Antigens, Publ: Quarterly Journal of Experimental Physiology, vol./Iss:, pp. 1-33, Date: Jan. 1, 1984.91Author: Van Rensen et al., Title: Liposomes with Incorporated MHC Class II/Peptide Complexes as Antigen Presenting Vesicles for Specific T Cell Activation, Publ: Pharmaceutical Research, vol./Iss: 16(2), pp. 198-204, Date: Jan. 1, 1999.92Author: Verma et al., Title: Gene Therapy-Promises, Problems and Prospects, Publ: Nature, vol./Iss: 389, pp. 239-242, Date: Sep. 18, 1997.93Author: Verma et al., Title: Gene Therapy�Promises, Problems and Prospects, Publ: Nature, vol./Iss: 389, pp. 239-242, Date: Sep. 18, 1997.94Author: Vidal et al., Title: Steric Stabilization of Polystyrene Colloids Using Thiol-ended Polyethylene Oxide, Publ: Polymers for Advanced Technologies, vol./Iss: 6, pp. 473-479, Date: Nov. 15, 1994.95Author: Walden et al., Title: Induction of Regulatory T-lymphocyte Responses by Liposomes Carrying Major Histocompatibility Complex Molecules and Foreing Antigen, Publ: Nature, vol./Iss: 315, pp. 327-329, Date: May 23, 1985.96Author: Wink et al., Title: Interation Between Plasmid DNA and Cationic Polymers Studied by Surface Plasmon Resonance Spectrometry Publ: Analytical Chemistry, vol./Iss: 71, pp. 801-805, Date: Jan. 1, 1999.97Author: Wuelling et al., Title: Nanometer Gold Clusters Protected by Surface-Bound Monolayers of Thiolated Poly (ethylene glycol) Polymer Electrolyte, Publ: Journal of the American Chemical Society, vol./Iss: 120, pp. 12696-12697, Date: Jan. 1, 1998.98Author:, Title: "Cancer", Publ: Taber's Cyclopedic Medical Disctionary, vol./Iss: Ed. 16, pp. 274, Date: Jan. 1, 1985.99Author:, Title: Appicants do not have translation; Concise Statement: This reference describes the use of acetal-PEG-dimethyllaminotheylpolymethacrylate as a dispersion stabilizer for fine particles of gold, Publ: Polymer Preprints, vol./Iss: 49(3), pp. 650, Date: Jan. 1, 2000.100Author:, Title: Australian Office Action-Application No. 2002259107, Publ: Australian Office Action, vol./Iss:, pp. 1-2, Date: Nov. 14, 2005.101Author:, Title: Australian Office Action�Application No. 2002259107, Publ: Australian Office Action, vol./Iss:, pp. 1-2, Date: Nov. 14, 2005.102Author:, Title: Canadian Office Action-2,309,604, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: Feb. 11, 2006.103Author:, Title: Canadian Office Action�2,309,604, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: Feb. 11, 2006.104Author:, Title: Canadian Office Action-2,309,604, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: May 18, 2006.105Author:, Title: Canadian Office Action�2,309,604, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: May 18, 2006.106Author:, Title: Canadian Office Action-Application No. 2,448,607, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: Apr. 7, 2009.107Author:, Title: Canadian Office Action�Application No. 2,448,607, Publ: Canadian Office Action, vol./Iss:, pp. 1-4, Date: Apr. 7, 2009.108Author:, Title: EPO Office Action cited in 02729092.3 (CYT0091EP), Publ: EPO Office Action, vol./Iss:, pp. 1-4, Date: Oct. 23, 2009.109Author:, Title: EPO Search Report cited in EP Application No. 05722719.9 (CYT-0094EP) Publ: EPO Search Report, vol./Iss:, pp. 1-4, Date: Sep. 15, 2010.110Author:, Title: EPO Search Report-98957757.2, Publ: EPO Search Report, vol./Iss:, pp. 1-3, Date: Oct. 31, 2003.111Author:, Title: EPO Search Report�98957757.2, Publ: EPO Search Report, vol./Iss:, pp. 1-3, Date: Oct. 31, 2003.112Author:, Title: EPO Search Report-98957757.2, Publ: EPO Search Report, vol./Iss:, pp. 1-4, Date: Oct. 31, 2003.113Author:, Title: EPO Search Report�98957757.2, Publ: EPO Search Report, vol./Iss:, pp. 1-4, Date: Oct. 31, 2003.114Author:, Title: Japanese Office Action cited in 2000-520162 (with English translation), Publ: Japanese Office Action, vol./Iss:, pp. 1-3, Date: Jun. 4, 2010.115Author:, Title: Japanese Office Action cited in 2000-520162 (with English translation), Publ: Japanese Office Action, vol./Iss:, pp. 1-3, Date: Oct. 22, 2009.116Author:, Title: Japanese Office Action cited in 2000-520162 (with English translation), Publ: Japanese Office Action, vol./Iss:, pp. 1-7, Date: Apr. 14, 2009.117Author:, Title: Japanese Office Action cited in 2002-584861 (with English translation), Publ: Japanese Office Action, vol./Iss:, pp. 1-10, Date: Dec. 25, 2008.118Author:, Title: Japanese Office Action cited in 2006-551620 (with English translation), Publ: Japanese Office Action, vol./Iss:, pp. 1-4, Date: Jul. 13, 2010.119Author:, Title: Office Action-Peoples Republic of China-Application No. 200580009719.0 (with English translation) Publ: Peoples Republic of China-Office Action, vol./Iss:, pp. 1-15, Date: Mar. 20, 2009.120Author:, Title: Office Action�Peoples Republic of China�Application No. 200580009719.0 (with English translation) Publ: Peoples Republic of China�Office Action, vol./Iss:, pp. 1-15, Date: Mar. 20, 2009.121Author:, Title: PCT International Search Report and Written Opinion issued in PCT/US08/77239 (CYT-0166) Publ: PCT International Search Report, vol./Iss:, pp. 107, Date: Dec. 5, 2008.122Author:, Title: USPTO Office Action-cited in 09/189,657, Publ: USPTO Office Action, vol./Iss:, pp. 1-15, Date: Apr. 11, 2008.123Author:, Title: USPTO Office Action�cited in 09/189,657, Publ: USPTO Office Action, vol./Iss:, pp. 1-15, Date: Apr. 11, 2008.124Author:, Title: USPTO Office Action-cited in 10/672,144 (CYT-0027), Publ: USPTO Office Action, vol./Iss:, pp. 1-5, Date: Nov. 15, 2010.125Author:, Title: USPTO Office Action�cited in 10/672,144 (CYT-0027), Publ: USPTO Office Action, vol./Iss:, pp. 1-5, Date: Nov. 15, 2010.126Author:, Title: USPTO Office Action-cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-10, Date: Apr. 15, 2009.127Author:, Title: USPTO Office Action�cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-10, Date: Apr. 15, 2009.128Author:, Title: USPTO Office Action-cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-6, Date: Aug. 5, 2010.129Author:, Title: USPTO Office Action�cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-6, Date: Aug. 5, 2010.130Author:, Title: USPTO Office Action-cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-8, Date: Jan. 20, 2010.131Author:, Title: USPTO Office Action�cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-8, Date: Jan. 20, 2010.132Author:, Title: USPTO Office Action-cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-8, Date: Oct. 17, 2007.133Author:, Title: USPTO Office Action�cited in 10/672,144, Publ: USPTO Office Action, vol./Iss:, pp. 1-8, Date: Oct. 17, 2007.134Author:, Title: USPTO Office Action�cited in 11/016,204, Publ: USPTO Office Action, vol./Iss:, pp. 1-36, Date: Jul. 7, 2009.135Author:, Title: USPTO Office Action-cited in 12/250,126, Publ: USPTO Office Action, vol./Iss:, pp. 1-12, Date: Jun. 7, 2010.136Author:, Title: USPTO Office Action�cited in 12/250,126, Publ: USPTO Office Action, vol./Iss:, pp. 1-12, Date: Jun. 7, 2010.137Author:, Title: USPTO Office Action�cited in 12/708,326 (CYT-0110), Publ: USPTO Office Action, vol./Iss:, pp. 1-15, Date: Nov. 8, 2010.138Office Action in U.S. Appl. No. 11/046,204, filed Oct. 16, 2008.Referenced byCiting PatentFiling datePublication dateApplicantTitleUS20120134956 *Oct 26, 2011May 31, 2012Cytimmune Sciences, Inc.Colloidal metal compositions and methods* Cited by examinerClassifications U.S. Classification436/525, 436/518International ClassificationG01N33/553, C07K14/525, C07K16/24, A61K47/48, A61K9/00, A61K39/39Cooperative ClassificationA61K38/191, A61K49/0056, A61K39/39, C07K14/525, A61K47/48215, A61K2039/55516, A61K38/39, A61K2039/55522, C07K16/241, A61K2039/55505, A61K49/0013, A61K49/0065, A61K49/0017, A61K51/1244, A61K47/48861European ClassificationC07K14/525, A61K49/00P4, C07K16/24B, A61K49/00P4F8R, A61K39/39, A61K49/00P12, A61K38/39, A61K51/12H, A61K38/19A, A61K49/00P4F, A61K47/48K6P, A61K47/48W8BLegal EventsDateCodeEventDescriptionSep 5, 2014ASAssignmentOwner name: CYTIMMUNE SCIENCES, INC., MARYLANDFree format text: RELEASE OF SECURITY INTEREST;ASSIGNOR:ITANI, HIDETAKA KENTARO;REEL/FRAME:033692/0418Effective date: 20140331Sep 18, 2009ASAssignmentEffective date: 20090917Owner name: ITANI, HIDETAKA KENTARO, PENNSYLVANIAFree format text: SECURITY AGREEMENT;ASSIGNOR:CYTIMMUNE SCIENCES, INC.;REEL/FRAME:023254/0076RotateOriginal ImageGoogle Home - Sitemap - USPTO Bulk Downloads - Privacy Policy - Terms of Service - About Google Patents - Send FeedbackData provided by IFI CLAIMS Patent Services©2012 Google